scholarly journals Octreotide Acetate

2020 ◽  
Author(s):  
Keyword(s):  
Octreotide Acetate

Case of Recovery from Late Chylothorax after Surgery for Esophageal Cancer following Administration of Octreotide Acetate and Injection of OK-432 into the Pleural Cavity

2006 ◽  
Vol 57 (1) ◽  
pp. 35-39 ◽  
Author(s):  
Shingo Tachibana ◽  
Yoshiaki Osaka ◽  
Sumito Hoshino ◽  
Masumi Yamazaki ◽  
Yu Takagi ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Pleural Cavity ◽  
Octreotide Acetate

A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107).

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. 360-360
Author(s):  
Rocio Garcia-Carbonero ◽  
Marta Benavent ◽  
Paula Jiménez Fonseca ◽  
Daniel Castellano ◽  
Teresa Alonso ◽  
...  
Keyword(s):  
Disease Progression ◽  
Phase Ii ◽  
Primary Tumor ◽  
Phase Iii ◽  
Study Entry ◽  
Tumor Site ◽  
Double Blind ◽  
Primary Tumor Site ◽  
Octreotide Lar ◽  
Octreotide Acetate

360 Background: Angiogenesis plays an important role in NET development and progression. Axitinib is a potent and selective VEGFR-1,2,3 inhibitor, with proven activity against several vascular-dependent solid tumors. The aim of this randomized, double-blind phase II/III study was to assess the efficacy of axitinib in patients with advanced G1-2 extra-pancreatic NETs. Methods: Eligible pts were randomized (1:1) to receive octreotide LAR (30 mg IM q4w) with axitinib (5 mg BID) or placebo BID until disease progression or unacceptable toxicity. Pteswere stratified by time from diagnosis to study entry ( > or < 12m), primary tumor site (GI tract vs non-GI) and Ki-67 index (< 5% vs > 5%). Prior therapy with SSA, IFN and up to 2 lines of systemic treatment was allowed, but not prior VEGF- or VEGFR-targeted drugs. Clinical and/or radiological disease progression within 12 months prior to study entry was required. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), time to progression, overall response rate (ORR), duration of response, biochemical response and safety. Results: 256 pts were randomized (106 in the Phase II part, and 150 additional pts in the Phase III part), 126 to axitinib and 130 to placebo. The main characteristics of the study population were: median age 61 years (range: 21-85), 52% male, PS 0-1 (64-35%), G1-2 (29%-71%), primary tumor site GI (40%)-Lung (17%)-Other (32%). Prior therapies included: SSA (46%), everolimus (13%), chemotherapy (13%), TACE (5%) and PRRT (2%). ORR was significantly higher in axitinib- vs placebo-treated patients (17.5% vs 3.8%, p = 0.0004). PFS per investigator assessment also favored axitinib vs placebo-treated patients, although the difference did not reach statistical significance (median PFS 17.2 vs 12.3 months, respectively, HR 0.816, p = 0.169). Grade 3-4 treatment-related AEs occurred more frequently in the axitinib vs placebo arm (52% vs 13.8%), and included hypertension (21% vs 6 %), cardiac disorders (3.2% vs 0.7%), diarrhoea (13% vs 1.5 %), asthenia (9% vs 3%) and nausea&vomiting (2% vs 0.7%). There were 3 treatment-related deaths, 1 in the axitinib arm (cardiac failure) and 2 in the placebo arm (myocardial infarction and hepatorenal syndrome). Conclusions: Although the study failed to demonstrate a significant PFS benefit per investigator assessment, axitinib in combination with octreotide LAR demonstrated activity and had a tolerable safety profile in patients with advanced G1-2 extra-pancreatic NETs. Data base cleaning and central blinded radiological PFS assessment are currently ongoing. Clinical trial information: NCT01744249.

Effect of the Somatostatin Analogue Octreotide Acetate on Hemostasis in Humans

1991 ◽  
Vol 66 (3) ◽  
pp. 283-286 ◽  
Author(s):  
THOMAS E. WITZIG ◽  
LARRY K. KVOLS ◽  
CHARLES G. MOERTEL ◽  
E.J. WALTER BOWIE
Keyword(s):  
Somatostatin Analogue ◽  
Octreotide Acetate ◽  
Analogue Octreotide

THE EFFECT OF OCTREOTIDE ACETATE ON MEAL-STIMULATED EXOCRINE SECRETION IN CANINE PANCREATIC AUTOGRAFTS

1991 ◽  
Vol 52 (3) ◽  
pp. 453-456 ◽  
Author(s):  
PAUL J. GARVIN ◽  
FRANK R. BURTON ◽  
JEFFREY C. REESE ◽  
DAVID LINGLE ◽  
PRASHANT K. PANDYA ◽  
...  
Keyword(s):  
Exocrine Secretion ◽  
Octreotide Acetate

Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome

1990 ◽  
Vol 49 (6) ◽  
pp. 483-487 ◽  
Author(s):  
William O. Richards ◽  
Richard Geer ◽  
Thomas M. O'Dorisio ◽  
Tim Robarts ◽  
Kenneth L. Parish ◽  
...  
Keyword(s):  
Small Bowel ◽  
Dumping Syndrome ◽  
Bowel Motility ◽  
Small Bowel Motility ◽  
Octreotide Acetate

scholarly journals PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis

PPAR Research ◽  
2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Wen Bao ◽  
Rui Kong ◽  
Nan Wang ◽  
Wei Han ◽  
Jie Lu
Keyword(s):  
Combined Treatment ◽  
Inhibitory Effect ◽  
Water Withdrawal ◽  
Signal Pathways ◽  
Ppar Alpha ◽  
Octreotide Acetate ◽  
Treatment Measures ◽  
Synergistic Inhibitory Effect ◽  
First Time ◽  
Alpha Agonist

At present, there are more and more patients with acute hypertriglyceridemia pancreatitis in clinical practice. Common treatment measures include fasting and water withdrawal, fluid resuscitation, and somatostatin. In recent years, studies have pointed out that the PPARa agonist fenofibrate may help improve the condition of such patients. Therefore, through clinical research and analysis, we reported for the first time that fenofibrate combined with octreotide acetate has a more excellent effect in the treatment of patients with acute hypertriglyceridemia pancreatitis, and from the perspective of signal pathways, we revealed that the combination of the two drugs has an effect on NF-κB P65. The synergistic inhibitory effect proves that the combined treatment is beneficial to control inflammation, protect liver function, and improve the prognosis of patients. It is worthy of clinical promotion.

scholarly journals Crucial Role of Insulin in Leptin Maintenance. Profound Decrease in Serum Leptin by Octreotide Acetate in Insulinoma Subjects.

2000 ◽  
Vol 47 (3) ◽  
pp. 359-364 ◽  
Author(s):  
TOMOATSU NAKAMURA ◽  
SHOICHIRO NAGASAKA ◽  
SAN-E ISHIKAWA ◽  
MUTSUKO NONAKA ◽  
KAZUTOSHI FUJIBAYASHI ◽  
...  
Keyword(s):  
Crucial Role ◽  
Serum Leptin ◽  
Octreotide Acetate

Fragmented particles containing octreotide acetate prepared by spray drying technique for dry powder inhalation

2018 ◽  
Vol 8 (3) ◽  
pp. 693-701 ◽  
Author(s):  
Ailin Hou ◽  
Lu Li ◽  
Ying Huang ◽  
Vikramjeet Singh ◽  
Chune Zhu ◽  
...  
Keyword(s):  
Spray Drying ◽  
Dry Powder Inhalation ◽  
Dry Powder ◽  
Octreotide Acetate
Sign in / Sign up

Export Citation Format

Share Document